Skip to main content

Kisunla News

Anti-Amyloid Drug Shows Promise In Preventing Alzheimer's

MONDAY, March 24, 2025 – The best evidence yet that cutting-edge Alzheimer’s disease drugs might indeed ward off the degenerative brain disease has emerged from a small-scale study. An experimental d...

Alzheimer's Drugs May Work in Whole New Way, Study Finds

THURSDAY, Sept. 11, 2024 – Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been approved by the U.S. Food and Drug Administration...

FDA Approves New Drug to Treat Alzheimer's, Kisunla

TUESDAY, July 2, 2024 – A new drug to treat Alzheimer's disease was approved by the U.S. Food and Drug Administration on Tuesday. In clinical trials, donanemab (Kisunla) modestly slowed the pace of...

FDA Approves Kisunla (donanemab-azbt) for the Treatment of Early Symptomatic Alzheimer's Disease

INDIANAPOLIS, July 2, 2024 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) approved Kisunla™ (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion), Eli Lilly and Company's ...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Alzheimer's Disease

Kisunla patient information at Drugs.com